<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003345</url>
  </required_header>
  <id_info>
    <org_study_id>97-121</org_study_id>
    <secondary_id>CDR0000066322</secondary_id>
    <secondary_id>NCI-H98-0013</secondary_id>
    <nct_id>NCT00003345</nct_id>
  </id_info>
  <brief_title>Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer</brief_title>
  <official_title>Phase II Trial of Cisplatin and Irinotecan in Patients With Suboptimally Debulked, Incompletely Responding Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining cisplatin and irinotecan in&#xD;
      treating patients who have ovarian, fallopian tube, or peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the antitumor effect of weekly cisplatin and irinotecan in patients&#xD;
      with suboptimally debulked ovarian, fallopian tube, or peritoneal cancer and persistently&#xD;
      elevated serum values of CA125 after 3 courses of standard therapy with paclitaxel and either&#xD;
      carboplatin or cisplatin. II. Evaluate the toxicity, both qualitative and quantitative, of&#xD;
      this regimen in this patient population. III. Evaluate the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 90&#xD;
      minutes. Treatment is administered weekly for 4 weeks (days 1, 8, 15, and 22) followed by 2&#xD;
      weeks of rest. Patients receive at least 3 courses (18 weeks) of therapy in the absence of&#xD;
      disease progression or unacceptable toxicity. If patients demonstrate complete response to&#xD;
      treatment, they are encouraged to undergo second-look laparoscopy or laparotomy. Quality of&#xD;
      life is assessed before treatment, after the first course, and then after every 2 courses of&#xD;
      therapy. Patients are followed 30 days after the last treatment and then for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be 12-35 patients accrued into this study over 18-24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed epithelial carcinoma of the ovary,&#xD;
        fallopian tube, or peritoneum At least 3 prior courses of standard platinum-paclitaxel&#xD;
        regimen Patients with taxane allergy may enter this study after 3 courses of platinum based&#xD;
        treatment CA125 at least 35 measured within 30 days of commencement of treatment Measurable&#xD;
        disease not required No CNS metastases, carcinomatous meningitis or interstitial pulmonary&#xD;
        fibrosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life&#xD;
        expectancy: Not specified Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count&#xD;
        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no&#xD;
        greater than 1.5 mg/dL Calcium less than 12.0 mg/dL Cardiovascular: No unstable angina No&#xD;
        New York Heart Association grade III or IV cardiac disease Pulmonary: See Disease&#xD;
        Characteristics Other: No active or uncontrolled infection No history of seizures No known&#xD;
        Gilbert's Disease No medical or psychiatric conditions that makes patient a poor risk for&#xD;
        participation in this study Not pregnant or lactating Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior&#xD;
        irinotecan or topotecan Endocrine therapy: Not specified Radiotherapy: No prior&#xD;
        radiotherapy to the pelvis Surgery: At least 4 weeks since prior surgery and recovered&#xD;
        Other: No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Spriggs, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2004</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

